Rocket One's Hoth Ends HT-001 Phase 2a Trial Early on Positive Interim Results
Bitget2026/11/03 13:18- Rocket One's Hoth Therapeutics is ending its HT-001 Phase 2a trial early following strong interim efficacy findings announced today.
- The investigational topical treatment targets skin toxicity associated with EGFR inhibitor cancer therapies.
- Hoth plans to present the data to the FDA to seek feedback on a potential Phase 3 program.
- A Phase 3 launch depends on regulatory feedback and completion of required development work.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
HIVE’s Bitcoin output jumps 49%, but mining revenue still falls
Asia-Pacific stock markets follow the overnight rally in US tech stocks, with South Korea's KOSPI up 5% at the open, SK Hynix surging more than 7%, and Nikkei 225 rising over 2%.
This round of rebound occurred after the market experienced severe turbulence. Last week, concerns over the potential for stricter regulation of the artificial intelligence industry, due to the US Congressional election results, triggered a large-scale sell-off in chip stocks. Several market participants believe that this rebound indicates investors have not abandoned the AI trading narrative, and last week’s sell-off was more about position adjustments rather than a trend reversal.
Barrick’s Marquee gold project faces hazy study timing
Japanese and South Korean stock markets open
Crypto prices
More
